SCHEMBL4230349

SCHEMBL4230349

Cc1nc2ccccc2c(C(=O)O)c1N

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 3/20 0.70
HSD17B10 Q99714 3/20 0.66
TP53 P04637 1/20 0.66
KMT2A Q03164 3/20 0.60
MEN1 O00255 1/20 0.60
ALDH1A1 P00352 3/20 0.58
HPGD P15428 2/20 0.58
CYP1A2 P05177 1/20 0.58
NUDT1 P36639 1/20 0.58
TSHR P16473 2/20 0.55
SMYD3 Q9H7B4 2/20 0.53
DHODH Q02127 2/20 0.53
HTT P42858 1/20 0.51
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
LMNA P02545 1/20 0.49
GPR3 P46089 1/20 0.48
KDM4E B2RXH2 2/20 0.48
CYP2D6 P10635 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19691190 0.88 HSD17B10 (0.64) PDE10AHSD17B10TP53KMT2AMEN1
SCHEMBL620119 0.86 HSD17B10 (0.81) PDE10AHSD17B10TP53KMT2AMEN1
SCHEMBL353201 0.84 PDE10A (0.77) PDE10AHSD17B10TP53KMT2AMEN1
SCHEMBL29415444 0.84 PDE10A (0.77) PDE10AHSD17B10TP53KMT2AMEN1
SCHEMBL13957825 0.82 PDE10A (1.00) PDE10AHSD17B10TP53KMT2AMEN1
SCHEMBL1527122 0.81 PDE10A (0.72) PDE10AHSD17B10TP53KMT2AMEN1
SCHEMBL3908668 0.79 DHODH (0.71) PDE10ANUDT1TSHRDHODHLMNA
SCHEMBL6654332 0.79 HSD17B10 (1.00) PDE10AHSD17B10TP53KMT2AMEN1
SCHEMBL29952587 0.79 HSD17B10 (0.71) PDE10AHSD17B10TP53KMT2AMEN1
SCHEMBL9652593 0.79 HSD17B10 (0.81) PDE10AHSD17B10TP53KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090156575-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES ASTRAZENECA AB (SE) 2009-06-18 US disclosed
EP-1926730-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES AstraZeneca AB (SE) 2008-06-04 EP disclosed
WO-2007030061-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES ASTRAZENECA AB (SE) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156575-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES CCR8, CCR1, CCR10 PDE10A 1968/4885HSD17B10 2881/4885TP53 3230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.